- 65% mean reduction in total IgG was observed from baseline to end of treatment, with a pharmacodynamic (PD) response nearly identical to modeled predictions for dosing regimen tested in trial
- IMVT-1401 was safe and generally well-tolerated with no serious adverse events (SAEs), no withdrawals due to adverse events (AEs), and no headaches
- 4/7 patients (57%) improved by ≥ 2 points on the Clinical Activity Score (CAS) and 3/7 patients (43%) achieved a proptosis response
- Results establish first proof of concept for an anti-FcRn antibody in Thyroid Eye Disease
Catalyst
Slingshot members are tracking this event:
Immunovant (IMVT) Announces Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401 Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye Disease
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IMVT |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 30, 2020
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Imvt-1401, Anti-fcrn Agents, Thyroid Eye Disease, Subcutaneous Injection
